HCLTECH
11.1.2024 14:05:00 CET | Business Wire | Press release
HCLTech, a leading global technology company, will join forces with key stakeholders from across the globe at the 54th Annual Meeting of the World Economic Forum (WEF) in Davos from Jan. 15–19, 2024. The company will contribute to deliberations on this year’s theme of “Rebuilding Trust” and discovering solutions with transparency, consistency and accountability.
HCLTech will be represented by its Chairperson Roshni Nadar Malhotra, CEO and Managing Director C Vijayakumar, Chief Technology Officer Kalyan Kumar; Chief Growth Officer for Europe and Africa, Ashish Kumar Gupta; President, Digital Foundation Services, Jagadeshwar Gattu; Global Head, Financial Services, Srinivasan Seshadri; Chief Marketing Officer Jill Kouri and Global Head, Sustainability, Santhosh Jayaram.
HCLTech will once again host guests at its pavilion at the iconic Promenade 66 which will be fully powered by locally produced green energy, underscoring the company’s commitment to a sustainable planet. In addition to its differentiated portfolio of services across digital, engineering, cloud, AI and software, HCLTech will showcase its award-winning sustainability solution, Net Intelligent Zero (NIO), at the pavilion with a live data feed.
This year, HCLSoftware makes its WEF debut with a dedicated lounge within the HCLTech pavilion. Chief Revenue Officer Rajiv Shesh and Chief Product Officer Kalyan Kumar will lead the HCLSoftware contingent that will showcase its cutting-edge software solutions that help enterprises navigate digital transformation.
HCLTech will participate in and host a series of panels and sessions on the future of technology, sustainability, diversity and inclusion in line with its brand purpose of bringing together the best of technology and its people to supercharge progress.
- The highlight this year will be the ‘Heroes of Progress’ reception on Jan. 17 to honor WEF Global Shapers who are making significant contributions to the fields of environment, women’s empowerment, art and sustainability.
- Roshni Nadar Malhotra, Chairperson, HCLTech is discussing the global water cycle and the potential of water as an enabler for SDGs on a panel on 'Out of Balance with Water' on Jan. 17, 15:00-15:45, Congress Center.
- Srinivasan Seshadri, Chief Growth Officer and Global Head, Financial Services, HCLTech, will lead an affiliate session on ‘Banking on trust through transformative tech’ on Jan. 16, 10:15-11:15 at Dome C, Ice Village.
- HCLTech is conducting broadcast sessions at its pavilion on Jan. 16, 17 and 18, 13:00–13:45. Dr. Saikat Chaudhuri, Innovation, Strategy and Engineering Professor, UC Berkeley will be moderating all three sessions with key industry leaders on: technology-led disruption, opportunities and impact; diversity-led progress for the future workforce; purpose-led sustainability agenda.
Additionally, HCL Group and Uplink, the open innovation platform of WEF, will announce the winners of this year’s Aquapreneur Challenge as part of their ongoing partnership.
To learn more about HCLTech@WEF 2024 visit World Economic Forum (WEF) 2024 at Davos | HCLTech.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240111423911/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 14:00:00 CEST | Press release
ArcGIS Velocity Brings Real-Time Data Ingestion, Analysis, and Automated Alerting to ArcGIS Enterprise Deployments Esri announces that ArcGIS Velocity is now available for ArcGIS Enterprise, enabling real-time data analytics and automated actions in self-hosted environments. This capability’s new deployment unifies real-time workflows across ArcGIS Online and ArcGIS Enterprise. This update benefits organizations across industries: public safety, transportation, logistics, and more. Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT),
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 12:00:00 CEST | Press release
$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer Transaction is structured to fund Agenus through key value-inflection points, including interim topline pathologic response data and interim and final event-free survival (EFS) analyses, with proceeds to fund Agenus operations through year-end 2031, assuming full warrant exercise ROBBIN target population in MSS colon cancer represents a >$7 billion addressable annual sales opportunity in the US for which no new therapies have been approved in over 20 years2,3 To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer Company to host conference call and webcast today at 8:30 a.m. ET Agenus Inc. (Nasdaq: AGEN), a leader in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom